JY BioMed

JY BioMed harnesses the power of engineered immune cells and biologics to treat cancer, chronic inflammation, and degenerative diseases.

[JY BioMed @JY_BioMed]

PD-L1 blockade further restored antitumor activity.
Published in Immunobiology (Elsevier, 2026).

👉 https://t.co/ofW0FT8zv2

Currently based on preclinical research; clinical validation is ongoing.

#JYBioMed #LiverCancer #HCC #GammaDeltaTCells #TaiwanBiotech

[JY BioMed @JY_BioMed]

Most liver cancer patients are diagnosed at late stage — when options run out.

Existing immunotherapies face challenges in the liver's naturally immune-tolerant environment.

JY BioMed is exploring γδ T cells as a potential approach.

[JY BioMed @JY_BioMed]

γδ T cells engage cancer cells without needing specific antigen recognition.

Unmodified. No genetic engineering. Preclinical observations: cytotoxic activity against HCC cell lines, tumor growth inhibition in mouse models, no significant systemic toxicity noted.

[JY BioMed @JY_BioMed]

#JYBioMed #SLScienceHolding

[JY BioMed @JY_BioMed]

🔔🎉 Congrats SL Science Holding (Nasdaq: SLBT) on ringing the Nasdaq bell! JY BioMed's GDT platform, licensed for glioblastoma's global clinical development, is proud to be part of this milestone.
Still preclinical, not yet approved.

https://t.co/toRE0xK5S6

[SL Science @SLScience_SLBT]

We remain focused on advancing our Gamma Delta (γδ) T cell platform across scientific, academic, and regulatory fronts — exploring its potential as a complementary approach to cancer treatment.

👉 Read the full press release: https://t.co/VQje7wa1IR

[JY BioMed @JY_BioMed]

Still in preclinical research, not yet approved by any regulatory authority. Safety and efficacy not established.

📖 Read more:
👉https://t.co/pm0otR3U3t

[JY BioMed @JY_BioMed]

Biotech Glossary: What is a DMF?
Before a drug enters clinical trials, the FDA reviews a document detailing raw material manufacturing and quality, called a Drug Master File (DMF).
#JYBioMed

[JY BioMed @JY_BioMed]

JY BioMed has filed FDA DMFs for its UC-MSC platform and its derived exosomes, building a fully traceable quality framework from raw material to product.
#DMF #BiotechGlossary

[JY BioMed @JY_BioMed]

📖 Read more:
👉https://t.co/pm0otR3U3t

[JY BioMed @JY_BioMed]

Aug 21 marks National Senior Citizens Day. Frailty is a growing challenge in global aging care. JY BioMed's UC-MSC platform is in Phase 1 trials for frailty under FDA/TFDA oversight, backed by dual FDA DMF filings for UC-MSC and its exosomes.
#JYBioMed

[JY BioMed @JY_BioMed]

Early-stage research, not yet approved by any regulatory authority. Safety and efficacy not established.
#Frailty #CellTherapy

[JY BioMed @JY_BioMed]

Research stage, not yet approved for clinical use.
#BrainCancer #Glioblastoma #JYBioMed
📖 Read more:
👉https://t.co/3JmmqQ7Piy

[JY BioMed @JY_BioMed]

Last time we introduced the three gates in our brain cancer γδT cell research: reach, survive, maintain function. Today, digging into gate three. Why do cells struggle to hold on after breaking in? 🧠

[JY BioMed @JY_BioMed]

Another key concept: off-the-shelf cell therapy. γδT cells recognize tumors without matching, meaning they could be pre-manufactured and ready when needed, crucial for patients racing against time.

[JY BioMed @JY_BioMed]

Because tumors actively create a low-oxygen, low-glucose, immunosuppressive environment, like a fortress built on purpose. Even immune cells that break in often lose their fighting power.

[JY BioMed @JY_BioMed]

Selected Media Coverage
Commercial Times: https://t.co/6iFTFYJEBF

📖 Read more:
👉https://t.co/3JmmqQ7Piy

#BrainCancer #Glioblastoma #JYBioMed

[JY BioMed @JY_BioMed]

JY BioMed unveils a GDT cell therapy framework for glioblastoma, building a new paradigm for cell therapy in Taiwan. GBM is one of the most aggressive brain tumors in adults, with survival still limited. We're taking it on with γδT immune cells. 🧠

[JY BioMed @JY_BioMed]

Chairman Dr. Ethan Shen and CMO Dr. Benjamin Zhang, with Taipei Medical University's neurosurgery team, proposed a complete clinical development framework, published in the journal Biomedicines.

[JY BioMed @JY_BioMed]

γδT cells recognize tumors without matching, ideal for off-the-shelf therapy. The real challenge: three gates. Reaching the tumor, surviving inside it, maintaining function in a low-oxygen, low-glucose environment.

[JY BioMed @JY_BioMed]

Preclinical stage, not yet approved for clinical use.
#WorldLungCancerDay #LungCancer #TaiwanBiotech #JYBioMed

📖 Read more:
👉https://t.co/Jg8PdNyTY7

[JY BioMed @JY_BioMed]

August 1 is World Lung Cancer Day. Non-smokers get lung cancer too, and not in small numbers. Lung cancer is the world's leading cause of cancer death, claiming about 1.8 million lives in 2022 alone. 🫁